U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072169) titled 'A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)' on May 26.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.
Study Start Date: May 26
Study Type: INTERVENTIONAL
Condition:
B-cell Non-Hodgkin Lymphoma
Intervention:
DRUG: ABO2203 Injection
SC or IV
Recruitment Statu...